ADVFN Logo
Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
Merus NV

Merus NV (2GH)

41.20
0.40
( 0.98% )
Updated: 10:21:12
Realtime Data

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
41.20
Bid
41.20
Ask
41.60
Volume
49
41.20 Day's Range 41.20
26.40 52 Week Range 58.50
Previous Close
40.80
Open
41.20
Last Trade
49
@
41.2
Last Trade Time
02:00:45
Average Volume (3m)
239
Financial Volume
-
VWAP
-

2GH Latest News

Merus gibt Verabreichung von petosemtamab an ersten Patienten in Phase-II-Studie bei 3L+ mCRC bekannt

Merus gibt Verabreichung von petosemtamab an ersten Patienten in Phase-II-Studie bei 3L+ mCRC bekannt UTRECHT, Niederlande und CAMBRIDGE, Massachusetts, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Merus...

Merus annonce le traitement du premier patient dans le cadre d’un essai de phase 2 portant sur le pétosemtamab dans le CCRm en 3e ligne et lignes ultérieures

Merus annonce le traitement du premier patient dans le cadre d’un essai de phase 2 portant sur le pétosemtamab dans le CCRm en 3e ligne et lignes ultérieures UTRECHT, Pays-Bas et CAMBRIDGE...

Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC

Merus announces First Patient Dosed in Phase 2 Trial of Petosemtamab in 3L+ mCRC UTRECHT, The Netherlands and CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS), a...

Les données intermédiaires de Merus portant sur le pétosemtamab continuent de démontrer une activité cliniquement significative dans le traitement de 2e ligne et lignes ultérieures du CETC r/m

Les données intermédiaires de Merus portant sur le pétosemtamab continuent de démontrer une activité cliniquement significative dans le traitement de 2e ligne et lignes ultérieures du CETC r/m...

Zwischenergebnisse der Monotherapie mit Petosemtamab von Merus zeigen weiterhin klinisch signifikante Aktivität bei 2L+ r/m HNSCC

Zwischenergebnisse der Monotherapie mit Petosemtamab von Merus zeigen weiterhin klinisch signifikante Aktivität bei 2L+ r/m HNSCC Studie mit Petosemtamab in Kombination mit Pembrolizumab bei 1L...

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC

Merus’ Petosemtamab Monotherapy Interim Data Continues to Demonstrate Clinically Meaningful Activity in 2L+ r/m HNSCC Petosemtamab in combination with pembrolizumab in 1L r/m PD-L1 expressing...

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en fonction des données de sécurité et d’efficaci

Merus annonce l’autorisation par la FDA de BIZENGRI® (zénocutuzumab-zbco) dans le traitement de l’adénocarcinome pancréatique NRG1+ et du cancer du poumon non à petites cellules (CPNPC) NRG1+, en...

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und Wirksamkeitsdaten aus der eNRGy-Studie bekannt

Merus gibt FDA-Zulassung von BIZENGRI® (Zenocutuzumab-zbco) für NRG1+-Adenokarzinome der Bauchspeicheldrüse und NRG1+-nicht-kleinzelligen Lungenkrebs (NSCLC) auf der Grundlage von Sicherheits- und...

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy Study

Merus Announces FDA Approval of BIZENGRI® (zenocutuzumab-zbco) for NRG1+ Pancreatic Adenocarcinoma and NRG1+ Non–Small Cell Lung Cancer (NSCLC) Based on Safety and Efficacy Data From the eNRGy...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.2-0.4830917874441.4444177541.05524957DE
4-0.599999-1.4354043405641.7999994439.79999935740.97710699DE
12-7.2-14.876033057948.451.539.623943.71980827DE
26-10.3-2051.55439.619845.44453536DE
5214.856.060606060626.458.526.419544.79762825DE
15617.473.109243697523.858.51918241.8565156DE
26017.473.109243697523.858.51918241.8565156DE

2GH - Frequently Asked Questions (FAQ)

What is the current Merus NV share price?
The current share price of Merus NV is 41.20 €
What is the 1 year trading range for Merus NV share price?
Merus NV has traded in the range of 26.40 € to 58.50 € during the past year

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
7KOCullinan Metals Corp
0.0216 €
(80.00%)
1.5k
A8DAb Science
2.035 €
(58.74%)
49.73k
RV0Torrent Gold Inc
0.138 €
(55.06%)
5.05k
ZK7Conduit Pharmaceuticals Inc
0.102 €
(45.71%)
20.05k
W4VAlphaGen Intelligence Corp
0.022 €
(41.94%)
437.05k
BZZBank of Montreal
9.695 €
(-89.54%)
802
L7C2Windfall Geotek Inc
0.003 €
(-64.71%)
1.32k
E3O1Nexoptic Technology Corp
0.0075 €
(-51.61%)
742
LL3PanGenomic Health Inc
0.0766 €
(-39.40%)
400
0PV2Moovly Media Inc
0.003 €
(-33.33%)
140.76k
Y31Infinitii Ai Inc
0.0635 €
(39.56%)
11.36M
76M0Realbotix Corp
0.356 €
(-7.29%)
3.84M
D7GNel ASA
0.27 €
(0.41%)
3.81M
3CPXiaomi Corporation
4.2505 €
(-5.68%)
3.52M
PF8European Lithium Limited
0.0286 €
(6.72%)
3.18M

Discussion

View Full Feed
2times2 2times2 4 minutes ago
The bid of ~140 M at 0001 seems serious (showed up yesterday after a while of no bid, and stayed this morning). If just some of that would be upgraded to hit the 0002s I expect the ask at 0002 to dissolve quickly (since folks would remove it with volume coming in). A pop seems likely....however, The
NAFS
sharkey1 sharkey1 4 minutes ago
Looks Good HGiIls, Elite has covered all 11 of those, I like the last one, the new facility has all state of the art,
should be good for 5 years
ELTP
mckvee mckvee 4 minutes ago
Not sure who has said "it's over", but yeah... we sure do appear to be bag holders and I've said that. If Vegas was laying odds that we'll get a PR of any significance we will move the needle on this company and stock price by April, my guess is that the odds would be VERY poor based on historical
ALRTF
valuemind valuemind 4 minutes ago
CRMD 400% undervalued to GERN, because
1) It is already profitable last quarter whereas GERN will continue to lose money in the forseable future;
2) its revenue will surpass GERN's during the first quarter of 2025 more likely than not;
3) Its market capitalization is only 1/4 of
GERN
tigerpac tigerpac 4 minutes ago
Convertible note holder is likely shorting this stock from near the highs this morning.
LIDR
STOCKMONSTER STOCKMONSTER 4 minutes ago
GLOBAL FATIGUE IS SETTING IN!!!!!!!!!!!!!!!!!! DUMP ORAMA TIME!!!!!!!!!!!!!!!!!!!!! SORRY SUCKERS!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! TRUMP HIGH IS OVER!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! MUAHAHAHAHAHAAHAHAHAHAHAHAAH!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!
DJI
boobb2 boobb2 4 minutes ago
Now at 0.58.....did hear that the company is more interested in getting its financials up to date ....so they can sell the company to a large entity
RGFC
955 955 4 minutes ago
...with O'Biden assistance no doubt.
vlispxpert vlispxpert 5 minutes ago
INO we going boom? stay tuned:

https://schrts.co/mrHIFFwm
INO
mrfence mrfence 5 minutes ago
A company that makes history is always has it's Pan Club, people that chase them with Frying Pans, LOL!
murph87 murph87 5 minutes ago
Enlighten us! _____
SOUN
gdog gdog 5 minutes ago
rprx bought 12.28 $25.00 sold yesterday $26.01 +$1.00
KISSINGER KISSINGER 5 minutes ago
You feeling ME Biatches??? I am your Master. NOT the PIMP PASSLEY!

You all getting WHIPSAWED SCHMUCKS
ZENA
fung_derf fung_derf 5 minutes ago
Is this the classic case of buy on rumor, sell on news?
SOUN
gp22 gp22 6 minutes ago
$LIDR & $BLIN red hot. Last micro-float "Technology Infrastructure" Sector play to rip is $MITQ @ .70s. Float 5.7M. Crowd will finding it.
BLIN LIDR MITQ
firebag1 firebag1 6 minutes ago
.33s a bit ago - should go over .45
RIME
Debunkinator Debunkinator 6 minutes ago
Buy: 51,594,138 Neutral: 14,152,416 Sell: 5,782,112
ASII
Mr.BMatty Mr.BMatty 6 minutes ago
Good idea. The more I read his/her post the more I worry my IQ level may lower. Thanks! Have a great day as well. Congrats on being a part of the ELTP shareholder community. I’m new to this message board but been around since 2009 and NOW is our time. The future is bright!
ELTP
Fallingknife75 Fallingknife75 6 minutes ago
When you know that those who talk the most trash on the company are actually here to buy shares, it's easy to ignore them, literally or figuratively.

Good times ahead,

Knife
RDAR
gp22 gp22 6 minutes ago
$LIDR & $BLIN red hot. Last micro-float "Technology Infrastructure" Sector play to rip is $MITQ @ .70s. Float 5.7M. Crowd will finding it.
BLIN LIDR MITQ

Your Recent History

Delayed Upgrade Clock